companies

Y Combinator is the start-up accelerator that funds hundreds of new companies a year in return for a small stake. Since 2014 it has backed a steady stream of companies going after cancer, from blood tests to engineered viruses.

Creator of Herceptin, Avastin, and Rituxan, and owner of Foundation Medicine; the company that defined antibody oncology.

The company that made radioligand therapy a business, with Pluvicto and Lutathera, and the maker of Kisqali and Gleevec.

Bought Seagen for $43B to become an ADC leader; also makes Ibrance, Lorbrena, Braftovi, and the first PROTAC.

Pioneer of checkpoint inhibitors (Opdivo, Yervoy), now betting on the first successful bispecific ADC and alpha radiopharmaceuticals.

Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines.

AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.

Johnson & Johnson leads in multiple myeloma (Darzalex, Carvykti, Tecvayli, Talvey) and in bispecific antibodies for lung cancer (Rybrevant).

Sanofi makes Sarclisa (isatuximab), now in a subcutaneous form approved in July 2026.

Amgen invented the BiTE T-cell engager format and the first KRAS inhibitor.

Takeda co-owns Adcetris outside the US and is developing STING-agonist conjugates and CAR-NK cells.

Eli Lilly makes Verzenio and Retevmo, as well as the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib.

A Boston investment firm that funds biotech companies both privately and on the stock market, and incubates its own. Its cancer bets include Aktis Oncology, CG Oncology and Bicara Therapeutics.

AbbVie owns Venclexta and Elahere, and bought Capstan, the leading in vivo CAR-T company.

Bayer owns Xofigo, the only approved alpha emitter, and is developing next-generation actinium PSMA agents.

Daiichi Sankyo is the Japanese company whose DXd payload technology created the best ADC platform in the industry.

Ipsen is the French pharma behind Onivyde (liposomal irinotecan) and the NALIRIFOX regimen, and marketer of tovorafenib in Europe.

Jiangsu Hengrui is China's largest oncology pharma, maker of pyrotinib and the HER2 ADC trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets.

A Cambridge, Massachusetts biotech-only venture firm that seeds and incubates new drug companies. Cancer companies it has built include Bicycle Therapeutics, Day One Biopharmaceuticals and Antares Therapeutics.

A life sciences venture firm that grew out of Frazier Healthcare Partners in Seattle and now operates independently, backing private and public biotech companies.

Genmab is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly, and (via ProfoundBio) rinatabart sesutecan.

Gilead owns Trodelvy (via the $21B Immunomedics deal) and the Kite CAR-T franchise.

Jazz Pharmaceuticals commercialises zanidatamab (Ziihera) outside Asia.

The strategic venture arm of Alexandria Real Estate Equities, the life science property company. It takes small stakes in many biotech start-ups, often its own tenants. Its web pages blocked automated access.

Astellas co-owns Padcev and makes Vyloy, the first Claudin 18.2 drug.

BeOne Medicines makes Brukinsa, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab.

Exact Sciences makes Cologuard and Oncotype DX and is launching Cancerguard MCED and Oncodetect MRD; it is being acquired by Abbott for $21B.

A San Francisco investment firm that funds healthcare companies at every stage with a data-science approach. Its cancer investments include CG Oncology, ALX Oncology, Kura Oncology and the blood-test company Delfi Diagnostics.

GSK makes Jemperli, Zejula, and the twice-approved myeloma ADC Blenrep.

Incyte makes pemigatinib, the first targeted drug approved for bile duct cancer (2020), and the JAK inhibitor ruxolitinib.

Regeneron makes Libtayo and has a large portfolio of CD3 bispecifics (odronextamab, linvoseltamab).

India's largest drug company, which owns the branded cancer drugs Odomzo and Yonsa in the US and bought the PD-L1 antibody maker Checkpoint Therapeutics in 2025.

Chinese biotech whose ivonescimab beat Keytruda head-to-head, and developer of the Nectin-4×TROP2 ADC.

CStone developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China.

The Hyderabad generics maker that launched the world's first rituximab biosimilar in 2007 and now sells oncology generics and biosimilars in India, the US and Europe.

Japanese pharma that makes lenvatinib (Lenvima), a first-line option in liver cancer and a partner of pembrolizumab in several tumours.

Jeito Capital is a Paris fund that writes large cheques for European biotech companies so they can take drugs through late-stage trials without selling early. Cancer medicines are a recurring theme.

Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026.

Lightspeed is a large Silicon Valley venture firm best known for software, whose health practice backs cancer diagnostics, AI drug discovery and digital oncology companies.

Logos Capital is a San Francisco healthcare investment firm that backs biotech companies from private rounds through their public life, and turns up repeatedly in cancer drug financings.

The company that made BRCA testing a business, now selling hereditary panels and the myChoice, EndoPredict and Prolaris tumour tests.

The oncology generics company at the centre of India's two landmark patent fights: the first compulsory licence, for sorafenib in 2012, and the Supreme Court's 2013 refusal of Novartis's imatinib patent.

The investment company of the Novo Nordisk Foundation, based near Copenhagen. It is one of the largest life science investors in the world and its venture portfolio includes cancer companies such as Myricx Bio, which Novartis agreed to buy.

A large New York healthcare investment firm that backs companies from start-up to public markets across the world. Its portfolio includes many cancer drug and diagnostics companies such as Adcendo, Adicet Bio and Alterome.

Servier is the private French pharma that brought vorasidenib, the first low-grade glioma drug, to market.

A San Francisco life sciences venture firm that builds biotech companies in its own laboratories in North America and Europe. It created the radiopharmaceutical company RayzeBio and backed Gritstone, Repare and Abdera.

Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets.

The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits.

Agilent makes the Dako PD-L1 IHC 22C3 and 28-8 companion diagnostics and the Omnis staining platform.

The life sciences and healthcare arm of the Silicon Valley venture firm Andreessen Horowitz (a16z). It backs founders who mix biology, software and care delivery, including a small number of cancer drug and diagnostics start-ups.

Bausch Health (formerly Valeant) is a diversified pharmaceutical company whose oncology-adjacent products include the retinoid bexarotene (Targretin) and imiquimod (Zyclara) for actinic keratosis.

India's largest biopharmaceutical company, founded by Kiran Mazumdar-Shaw in 1978, and the parent of Biocon Biologics, which makes low-cost copies of the antibodies trastuzumab and bevacizumab.

Biocon's biosimilars arm, one of the few companies outside the US and Europe with FDA- and EMA-approved cancer antibody biosimilars, and since 2022 the owner of Viatris's biosimilars business.

Private German pharma whose zongertinib became the first oral HER2 inhibitor for lung cancer.

Bpifrance is the French state investment bank. Its innovation funds and grants co-finance many French biotech, medtech and radiotherapy companies, so it appears in a lot of French oncology rounds.

A Boston biotech investment firm led by Bihua Chen that invests in private and public life sciences companies and is a frequent name in crossover rounds. Its website could not be reached at the time of research.

Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.

DCVC, once Data Collective, is a deep-tech venture firm whose DCVC Bio arm backs computational biology and cancer diagnostics companies.

Liquid biopsy leader: Guardant360 for genotyping, Reveal for MRD, Shield for screening.

Helsinn is a Swiss family-owned company focused on supportive cancer care: the antiemetics Aloxi and Akynzeo, and the topical nitrogen mustard Valchlor for cutaneous T-cell lymphoma.

Innovent makes sintilimab, China's best-selling PD-1 antibody, and has become a source of next-generation assets for Roche and Takeda.

Revolution Medicines is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer.

A Palo Alto life sciences investment firm founded by Srinivas Akkaraju that invests in private and public biotech companies. Its website could not be read at the time of research.

Sandoz, spun out of Novartis in 2023, is the world's largest generics and biosimilars company; in oncology it sells biosimilar filgrastim (Zarxio), pegfilgrastim (Ziextenzo) and rituximab, and holds the US application for nelarabine (Arranon).

Section 32 is a venture firm founded by the former head of Google Ventures that invests across biology, healthcare and computing, including AI-native cancer diagnostics and therapeutics companies.

SERB is a European specialty company focused on emergency and rescue medicines; in oncology it markets glucarpidase (Voraxaze) for toxic methotrexate levels and uridine triacetate (Vistogard) for fluorouracil overdose in Europe.

TCGX is a crossover fund: it invests in private biotech companies in the round or two before they list, then keeps holding the shares as public investors. Several cancer drug developers in OnCo raised from it.

Teva is the world's largest generic medicines company; its branded oncology products include omacetaxine (Synribo) for resistant chronic myeloid leukaemia, arsenic trioxide (Trisenox), bendamustine (Bendeka) and the G-CSF products Granix and Lonquex.

Private US company that took over Tecelra and lete-cel from Adaptimmune in 2025 and markets eflornithine (Iwilfin) for neuroblastoma.

The Rockefeller family's venture firm, formed in 1969, which invests in technology and healthcare companies from its Palo Alto and New York offices. Its website could not be read without JavaScript.

Veracyte makes the Decipher genomic classifier, the most-used gene-expression test in localised prostate cancer.

Diagnostics giant that makes the UroVysion bladder test, sells Freenome's blood test for bowel cancer, and is acquiring Exact Sciences.

BrightEdge is the American Cancer Society's own venture fund. It invests donated money in start-ups working on cancer and returns any gains to the charity's mission.

Amgen Ventures is the venture arm of the biotech company Amgen. It takes minority stakes in early companies whose science could matter to Amgen, including cancer drug and platform start-ups.

First company with FDA-cleared AI pathology tests that predict treatment benefit (prostate 2025, breast 2026).

Betta made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval.

Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.

CARsgen Therapeutics developed satri-cel, the first CAR-T approved for a solid tumour (gastric cancer, China).

A New York investment firm founded by Eli Casdin that invests in life sciences companies on both public and private markets. Its venture list includes cancer companies such as Black Diamond Therapeutics and Function Oncology.

CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.

Kinase-switch-control company behind ripretinib for GIST and vimseltinib for tenosynovial giant cell tumour; bought by Ono Pharmaceutical in 2024.

A New York healthcare investment firm that funds companies, runs its own drug discovery labs and a philanthropy arm. It founded and seeded Nuvalent, a lung cancer drug company that GSK agreed to buy for $10.6 billion.

EcoR1 Capital is a San Francisco investment fund that only invests in biotech, from private rounds to listed companies, and often leads the crossover financings of cancer drug developers.

F-Prime Capital is the venture firm that grew out of Fidelity's own money. It invests in healthcare and technology companies, including cancer diagnostics and therapeutics, from seed to growth.

Ferring is the private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.

A Dutch venture firm that funds European and North American biotech companies from formation to late-stage growth. Its homepage says it manages around EUR 5 billion across 11 funds.

Freenome makes SimpleScreen CRC, the second FDA-approved blood test for colorectal cancer screening (July 2026), commercialised by Abbott.

Gilde Healthcare is a Dutch investor with separate funds for venture-stage health companies and for established healthcare businesses, backing diagnostics, medical technology and therapeutics across Europe and the United States.

The Indian company whose trispecific antibody ISB 2001 for multiple myeloma was licensed to AbbVie in 2025 for 700 million dollars upfront, the largest deal for an Indian-discovered cancer drug.

Heron Therapeutics makes long-acting supportive-care injectables: the antiemetics Sustol (extended-release granisetron) and Cinvanti (aprepitant emulsion), plus the post-surgical analgesic Zynrelef.

A privately held Hyderabad generics group, the world's largest maker of HIV antiretrovirals, which launched Indian biosimilars of rituximab in 2015 and bevacizumab in 2016.

Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca.

Inventor of the ImmTAC soluble TCR bispecific; tebentafusp was the first to improve survival in a solid tumour.

Longwood Fund is a Boston venture firm that founds and funds early biotech companies, several of them in cancer.

McKesson Ventures is the venture arm of the drug distributor McKesson, which also owns the largest US community oncology network, so it backs companies that change how cancer care is delivered and paid for.

Menarini is the private Italian pharma that commercialises the first oral SERD, elacestrant.

Dutch bispecific antibody company behind zenocutuzumab and petosemtamab; acquired by Genmab in 2025.

A Boston biotech investor, formerly MPM Capital, that builds and funds companies and runs an Oncology Impact Fund that donates part of its profits to cancer research. It built Aktis Oncology and backs Cullinan Oncology and Tizona.

Designer of cleaner kinase inhibitors; zidesamtinib (ROS1) approved July 2026, neladalkib (ALK) next.

A Boston and Geneva venture firm that invests in medicines across oncology, immunology and rare disease. Its impact page lists cancer products it helped bring to patients, including the lung cancer drug Ibtrozi and the colorectal screening test Epi proColon.

Otsuka is a Japanese pharmaceutical group whose oncology portfolio centres on haematology: intravenous busulfan (Busulfex) and decitabine (Dacogen).

A New York healthcare investment firm founded by Joseph Edelman that runs a large public-market fund, a credit fund and, through Xontogeny, a venture fund for very early biotech companies.

Pfizer's corporate venture arm, which invests in early biotech companies in the areas Pfizer cares about, including cancer. Its oncology portfolio includes Artios Pharma, Crossbow Therapeutics and Strata Oncology.

A Boston venture firm with a long record of co-founding biotech companies with academic scientists such as Bob Langer. Its cancer companies include Syros Pharmaceuticals, Kronos Bio and the blood-test company Freenome.

Recordati is an Italian pharmaceutical group whose rare-disease arm markets oncology and haematology products in Europe, including siltuximab (Sylvant), chlormethine gel (Ledaga) and dinutuximab beta (Qarziba).

Sanofi's strategic venture fund, which invests in early biotech and digital health companies before they are ready to partner with or be bought by Sanofi. Cancer-related holdings include the radiopharmaceutical company AdvanCell and the immune checkpoint company Abcuro.

Sante Ventures is an Austin, Texas healthcare venture firm that invests early in medical devices, diagnostics, biotech and health technology, including cancer companies.

The world's largest vaccine maker by doses, which developed CERVAVAC, India's first home-made HPV vaccine, so that cervical cancer prevention no longer depends on imported shots.

Chinese biosimilar and biologics company whose PD-1 antibody serplulimab is approved in China and Europe for small-cell lung cancer.

SpringWorks developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas; Merck KGaA acquired it in 2025.

SystImmune developed iza-bren, the first bispecific ADC to win a phase 3 trial.

Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.

Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.

TerSera is a US specialty company whose oncology and supportive-care products include goserelin (Zoladex), rolapitant (Varubi) and telotristat ethyl (Xermelo) in the US.

A life sciences venture firm founded by scientists, doctors and investors that creates and funds biotech companies. Many of its companies treat cancer, including Aktis Oncology, Adcendo, Allogene and Halda Therapeutics.

A venture firm with offices in San Francisco and Boston that funds early-stage drug companies and also runs a public-market fund. Its cancer investments include the cell therapy company Artiva, the protein degrader pioneer Arvinas and Enliven Therapeutics.

Acrotech Biopharma, part of Aurobindo, owns the former Spectrum Pharmaceuticals haematology portfolio: the radioimmunotherapy Zevalin, pralatrexate (Folotyn), belinostat (Beleodaq) and vincristine liposome (Marqibo).

Adaptimmune developed Tecelra, the first TCR-T for a solid tumour, and sold the US rights to US WorldMeds in 2025 amid financial distress.

Adaptive Biotechnologies makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in ALL, myeloma, and CLL.

ADC Therapeutics developed Zynlonta and the PBD-payload ADC platform.

Adienne is a Swiss company specialising in haematology and transplantation medicines; it holds the US and EU authorisations for thiotepa (Tepadina).

Dutch maker of MammaPrint, the 70-gene breast cancer test validated in the MINDACT trial.

Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.

PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026.

UCL spin-out whose fast-off-rate CD19 CAR-T, obe-cel, was approved for adult ALL in 2024 with lower neurotoxicity than earlier products.

AVEO Oncology developed tivozanib and was acquired by LG Chem in 2023.

The life sciences investing arm of Bain Capital in Boston. It funds later-stage private and public biotech companies, including cancer drug developers such as Olema Oncology, Nuvalent, Revolution Medicines and Mersana.

Infusion pumps (Spectrum, Novum), elastomeric ambulatory pumps (Infusor), IV fluids and generic injectables.

Inventor of bicyclic peptide drug conjugates; its lead Nectin-4 conjugate was deprioritised in 2026 after regulatory feedback.

Biofrontera is a German dermatology company whose photodynamic therapy product Ameluz (aminolevulinic acid gel) with its RhodoLED lamp treats actinic keratosis and, in Europe, superficial basal cell carcinoma.

biolitec is a German medical laser company that holds the EU authorisation for temoporfin (Foscan), a photosensitiser for palliative photodynamic therapy of advanced head and neck cancer.

From COVID vaccine to a broad oncology pipeline: personalised vaccines, ADCs from China, and a PD-L1×VEGF bispecific sold to BMS for $11B.

A San Diego biotech investment firm that backs precision medicine companies from private rounds through public listing. Its venture highlights include cancer drug developers Mirati, G1 Therapeutics, Tango and Elevation Oncology.

Nuclear pharmacy network (>130 sites) that compounds and delivers SPECT and PET doses, and a distributor of oncology drugs to community practices.

Whole-exome and whole-transcriptome tumour profiling at scale, with a large real-world database.

Celcuity developed gedatolisib, approved in July 2026 for hormone-positive breast cancer.

CG Oncology developed cretostimogene, the oncolytic virus for early bladder cancer, and is filing for approval in 2026.

Chipscreen discovered chidamide (tucidinostat), the first original epigenetic cancer drug from China, approved in 2014 and later in Japan.

The Mumbai generics maker famous for a one-dollar-a-day HIV regimen, which sells oncology generics across India and Africa and in 2026 partnered with ImmunoACT to take Indian CAR-T therapy to Africa.

Citius Pharmaceuticals brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary.

Corcept is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.

CStone is a Chinese biotech whose PD-L1 antibody sugemalimab (Cejemly) was authorised in the EU in 2024 for first-line metastatic non-small cell lung cancer with chemotherapy.

Paediatric-first oncology company whose tovorafenib became the first targeted therapy for childhood low-grade glioma.

Elevar Therapeutics developed rivoceranib, whose combination with camrelizumab has beaten sorafenib in liver cancer but has been refused by the FDA three times on manufacturing grounds.

Small biotech developing lymph-node-targeted KRAS vaccines for pancreatic and colorectal cancer.

The life sciences venture arm of the Swedish investment group EQT, formerly the Amsterdam firm LSP (Life Sciences Partners). It funds European and US biotech and medtech companies, including in cancer.

ESSA Pharma developed masofaniten, an AR N-terminal-domain inhibitor whose phase 2 was stopped for futility in 2024-25.

Evive Biotech developed efbemalenograstim alfa (Ryzneuta), a long-acting G-CSF fusion protein for chemotherapy-induced neutropenia approved in the US in 2023 and the EU in 2024.

Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.

Maker of the FDA-approved FoundationOne CDx genomic test used across dozens of drug labels.

Peter Thiel's San Francisco venture firm, best known for SpaceX, Palantir and Anduril. Its public portfolio page does not name any cancer companies, so its relevance to oncology is limited.

Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.

GE HealthCare is a major maker of PET/CT, MRI, and CT scanners, and of PET tracers via Pharmaceutical Diagnostics.

A large venture firm founded in Cambridge, Massachusetts, that now spans seed to growth and even owns a hospital system. Its health portfolio includes the radiopharmaceutical company Alpha-9 Oncology and the radiology AI firm Aidoc.

Generative-AI protein design company (Flagship) that went public in 2026 and is testing an antibody that neutralises leaked ADC payload to reduce side effects.

GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market.

GRAIL developed Galleri, the multi-cancer blood test awaiting an FDA decision after a September 2026 advisory committee.

Alphabet's venture arm, established in 2009. It has backed some of the best-known cancer diagnostics companies, including Foundation Medicine, Grail, Freenome and Flatiron Health, as well as cancer drug developers such as Forty Seven and Gritstone.

Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026.

Hansoh makes aumolertinib, China's most prescribed third-generation EGFR lung cancer pill, and has licensed two ADCs to GSK.

The women's health company behind most 3D mammography machines, HPV and cytology testing, and the Breast Cancer Index.

IASO Bio developed eque-cel, the fully human BCMA CAR-T for myeloma approved in China in 2023 and partnered with Innovent.

Long-standing mammography computer-aided detection company whose ProFound AI was the first cleared for 3D mammography; acquired by RadNet in 2025.

Illumina is the dominant DNA sequencing platform underneath nearly every genomic test in oncology.

A Bengaluru cell therapy company that brought Barcelona's academic CD19 CAR-T to India as Qartemi, the country's second approved CAR-T, after the IMAGINE trial.

ImmunityBio makes Anktiva, the IL-15 superagonist approved with BCG for bladder cancer in 2024.

The IIT Bombay spin-off that won India's first CAR-T approval in 2023 with NexCAR19 and has treated more than 600 patients at a tenth of Western prices.

InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas.

InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.

Iovance makes Amtagvi, the first approved TIL therapy.

ITM is the largest non-carrier-added lutetium-177 supplier and the developer of ITM-11 (177Lu-edotreotide).

Jiangsu Hengrui is China's largest innovative pharma, maker of the PD-1 antibody camrelizumab and a broad ADC pipeline.

Johnson & Johnson's venture capital arm, one of the oldest corporate venture groups in healthcare. It invests alongside J&J's innovation centres and JLABS incubators, including in cancer companies.

JW Therapeutics, a Juno and WuXi AppTec joint venture, made relma-cel, the first CAR-T developed and manufactured in China to be approved.

Karyopharm makes selinexor, the first nuclear export inhibitor, approved in myeloma; its endometrial cancer bet failed in 2026.

Chinese biotech whose joint venture KYM Biosciences created the Claudin 18.2 ADC CMG901, licensed to AstraZeneca in 2023.

London AI company whose Mia breast screening reader was evaluated across NHS sites before its 2024 acquisition by RadNet's DeepHealth.

Vinod Khosla's Menlo Park venture firm, which backs bold early-stage technology companies including health and biology start-ups. Cancer-related bets include the blood-test company Guardant Health and the AI oncology start-up Radical Health.

Kura Oncology developed ziftomenib, the second menin inhibitor approved for leukaemia (November 2025), in partnership with Kyowa Kirin.

Kyowa Kirin is a Japanese biopharmaceutical company whose oncology products include mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma and toremifene (Fareston) for metastatic breast cancer.

Leadiant Biosciences (formerly Sigma-Tau) is an Italian rare-disease company that holds the US application for procarbazine (Matulane).

Legend Biotech is the Chinese-origin developer of Carvykti, the most effective myeloma CAR-T, with J&J.

Eli Lilly's investment arm, part of its Lilly Catalyze360 programme for early biotech companies. It co-invests with venture syndicates across all disease areas, including cancer.

MIT spin-out whose Lumisight dye and imaging system show leftover breast cancer in the lumpectomy cavity before the operation ends.

Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.

A New York venture firm that backs deep technology companies, from defence and AI to biology. Its biotech holdings include the AI drug discovery company Recursion and the imaging-based drug hunter Eikon Therapeutics.

MacroGenics is the antibody engineering company behind margetuximab and several bispecific and ADC programmes.

Prostate diagnostics company that bought Oncotype DX GPS from Exact Sciences and sells the Select mdx and Confirm mdx tests.

Moderna is the mRNA company whose personalised cancer vaccine intismeran won the first phase 3 in the class (August 2026).

German antibody company that acquired Constellation's BET inhibitor pelabresib and was itself bought by Novartis in 2024.

Merck & Co's corporate venture fund for digital health and healthcare services companies, known as MSD GHI outside North America. Its website is a JavaScript application whose content could not be read.

Natera makes Signatera, the dominant tumour-informed MRD test.

Cancer-focused reference lab for IHC, FISH, flow cytometry, and NGS, serving community oncology and pharma.

Northwest Biotherapeutics developed the DCVax-L dendritic cell vaccine for glioblastoma and is seeking UK approval on contested phase 3 data.

Novocure makes Optune tumour treating fields, approved in glioblastoma, lung, mesothelioma, and (2026) pancreatic cancer.

Purdue spin-out that developed Cytalux, the glowing dye that shows ovarian and lung cancer deposits during surgery.

Oxford company with the first FDA-cleared AI for judging whether a lung nodule on CT is likely to be cancer.

Orano Med is the leading lead-212 producer and the developer of 212Pb-DOTAMTATE (AlphaMedix).

New Zealand company behind the Cxbladder urine tests for bladder cancer.

MSK spin-out with the first FDA-cleared AI pathology product and the Virchow foundation model.

PETNET Solutions is the largest network of PET radiopharmacies in the US, producing FDG and PSMA tracers daily.

Spanish company that turns marine natural products into cancer drugs, including lurbinectedin and trabectedin.

Pierre Fabre is a French pharmaceutical and dermo-cosmetics group whose oncology franchise includes vinorelbine (Navelbine), vinflunine (Javlor) and the BRAF/MEK pair encorafenib and binimetinib in Europe.

Puma Biotechnology developed neratinib (Nerlynx), the extended-adjuvant HER2 pill.

QIAGEN is a sample-preparation and molecular-diagnostics company selling nucleic-acid extraction kits, therascreen companion diagnostics, and QCI Interpret software.

Quanta Therapeutics develops oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer.

RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.

RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.

RemeGen developed disitamab vedotin, China's first domestic ADC.

Oncolytic virus company whose RP1 (Tudriqev) was approved in August 2026 after an initial FDA rejection.

Commercialises olutasidenib (Rezlidhia), an IDH1 inhibitor for relapsed AML, alongside fostamatinib.

Radboud University spin-out whose Transpara software is the AI reader tested in the MASAI screening trial.

Allist is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR pill, partnered with ArriVent for the rest of the world.

Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer).

Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals.

Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs.

Sobi is a Swedish rare-disease company whose haematology and oncology supportive products include palifermin (Kepivance) for severe oral mucositis, avatrombopag (Doptelet) and emapalumab (Gamifant).

SOFIE Biosciences is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer [18F]FAPI-74 in pancreatic and gastro-oesophageal cancer.

One of Europe's oldest life sciences venture firms, based in Paris. It has backed cancer companies such as Innate Pharma, Crescendo Biologics and Hookipa, and its portfolio company Myricx was bought by Novartis.

A transatlantic biotech venture firm that began as GSK's corporate venture arm and now invests independently from London and the US West Coast. Many of its companies work on cancer, including Akamis Bio, Avenzo Therapeutics and Charm Therapeutics.

Sumitomo Pharma makes Orgovyx (relugolix), the first oral GnRH antagonist for prostate cancer.

Summit Therapeutics holds Western rights to ivonescimab and is running the global HARMONi trials.

Cell-free protein synthesis ADC company that refocused on exatecan and dual-payload ADCs, deprioritising its folate-receptor ADC luveltamab.

Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021.

A London-listed investment company that founds and funds UK life science companies and holds them for the long term. Its cancer companies include the CAR-T company Autolus and the precision oncology firms iOnctura and Mosaic Therapeutics.

Syndax developed the first menin inhibitor, revumenib.

Taiho Oncology makes Inqovi, the oral decitabine-cedazuridine that in May 2026 became the first all-oral hypomethylating backbone for venetoclax in AML.

Genomic testing plus one of the largest multimodal clinical datasets, used for AI models and trial matching.

Thermo Fisher is the largest life-science tools and services company, spanning Ion Torrent sequencing (Oncomine), viral vector and fill-finish manufacturing (Patheon), and the PPD clinical research organisation.

Third Rock Ventures builds biotech companies from scratch around a scientific idea, then funds and staffs them. Several of the best-known precision oncology companies of the last fifteen years started in its offices.

Chinese biotech running the first phase 3 of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs.

RAS/MAPK-pathway company whose avutometinib + defactinib combination became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer (May 2025).

Verity Pharmaceuticals is a Canadian specialty company that holds the US application for triptorelin (Trelstar) for advanced prostate cancer.

WuXi AppTec is the contract research and manufacturing giant that makes small molecules, including ADC payloads and linkers, for much of the global cancer pipeline, and the target of the US BIOSECURE Act.

MSK spin-out that commercialises naxitamab, the humanised anti-GD2 antibody for relapsed neuroblastoma, and develops pretargeted radioimmunotherapy.

A large Ahmedabad drug maker with oncology generics and biosimilars for India and US approvals for cancer generics such as enzalutamide.

Zymeworks invented zanidatamab and a hydrophilic TOP1 ADC platform (ZW191 FRα, ZW251 GPC3).

Leader in single-cell and spatial biology tools (Chromium, Visium, Xenium) used to dissect tumours.

Hungarian maker of Pannoramic slide scanners and the SlideViewer software, widely used in research and European clinical labs.

AbbVie's corporate venture arm, which invests in early-stage biotech companies in AbbVie's therapeutic areas including cancer. Its web pages blocked automated access at the time of research.

Abdera Therapeutics engineered antibodies that carry a radioactive isotope to cancer cells, tuning how long they circulate so more radiation reaches the tumour and less reaches healthy tissue. Its first medicine targets a protein on small cell lung cancer.

Abzena is a bioconjugation and biologics CDMO with the ThioBridge site-specific linker technology.

Acrivon Therapeutics uses a protein-activity test to pick the patients most likely to respond to its cancer drugs. Its lead drug blocks DNA damage checkpoint proteins and is being tested in womb and ovarian cancer.

Actinium Pharmaceuticals attaches the alpha-emitting isotope actinium-225 to antibodies to treat acute myeloid leukaemia and, more recently, solid tumours such as prostate and lung cancer. It is a small listed company whose lead programme is approaching new clinical milestones.

Adcendo is a Danish company developing antibody-drug conjugates, antibodies that deliver a cell-killing drug straight to cancer cells, against targets few others are pursuing. Its first medicines are in early human trials, including one for soft tissue sarcoma.

Adela is developing blood tests that read chemical marks across the whole genome of DNA fragments in the blood, first to check whether cancer is still present after treatment and later to screen for many cancers at once.

Adialante has redesigned MRI so it fits in a mobile clinic and is paid per scan, aiming to bring MRI cancer screening to any medical site, starting with prostate cancer.

Adicet makes off-the-shelf immune cell therapies from donor gamma delta T cells, a rarer type of T cell. Its lead programme is now aimed at lupus and other autoimmune diseases, with a prostate cancer candidate expected to enter the clinic in late 2026.

Adventris makes off-the-shelf cancer vaccines against KRAS, the most common cancer-driving gene, with the long-term idea of a yearly vaccine that prevents many cancers.

Affini-T engineers a patient's T cells with receptors that recognise mutated cancer driver proteins such as KRAS, and uses gene editing to make the cells more effective. It is an early clinical-stage company based near Boston.

Radiology AI company with the first FDA-cleared foundation-model triage platform (CARE, January 2026); oncology-relevant for incidental findings and workflow.

Aignostics is the Berlin pathology AI company that built the Atlas foundation model with Mayo Clinic.

Spatial proteomics (PhenoCycler, PhenoImager) used to map immune cells in tumours; agreed to be acquired by Quanterix (2025).

Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.

Leading GMP plasmid DNA and mRNA raw-material supplier, acquired by Danaher for $9.6B in 2021.

Alentis Therapeutics targets Claudin-1, a protein exposed on squamous cancers and scarred organs, with antibodies that either carry a cancer-killing drug or block disease signalling. Its first cancer medicine entered human trials in 2025.

Algen uses CRISPR screens read out at the single-cell level, plus machine learning, to find which RNA messages drive cancer and inflammation, and then designs drugs against them.

Alixia is developing drugs that act on the supporting cells and inflammation around a tumour as well as the cancer cells, to stop cancers from becoming resistant.

Allogeneic CAR-T leader: cema-cel (CD19) as MRD-guided first-line consolidation in lymphoma, and ALLO-316 (CD70) with responses in kidney cancer.

Allotera, formerly Wugen, makes off-the-shelf CAR T-cell therapies from healthy donor cells for T-cell leukaemias and lymphomas, which are hard to treat with conventional CAR T because the cancer cells look like the therapy cells. Its lead product is in a global pivotal trial.

Alpha Tau Medical places tiny radioactive seeds directly inside tumours so that short-range alpha radiation destroys the cancer from within. It is testing the approach in pancreatic, skin, head and neck, brain and prostate cancers.

Alpha-9 Oncology designs bespoke molecules that deliver radioactive isotopes to cancer cells, with early human trials under way in melanoma and in breast and other solid tumours.

Altay Therapeutics is developing small-molecule drugs for chronic liver disease, including the scarring that leads to liver cancer and liver cancer itself.

Aluna works with hospitals to build carefully curated cancer datasets and evaluation sets so that medical AI models can be trained and tested properly.

Ambagon Therapeutics designs small molecules that act like glue, locking a hub protein called 14-3-3 onto its partner proteins to switch them on or off. It is an early-stage company with cancer and brain disease programmes.

Amphista Therapeutics, based near Cambridge in the UK, designs small molecules that make cancer cells destroy specific proteins using a less common disposal enzyme called DCAF16. Its first drug, for acute myeloid leukaemia, was cleared to start human trials in 2026.

Amunix developed T-cell engager and cytokine cancer drugs with a protective mask that is clipped off by enzymes found in tumours, so the drugs become active mainly at the cancer. Sanofi agreed to buy the company in December 2021 for about $1 billion upfront.

Ananya Health makes a portable freezing device that lets a nurse in any clinic treat abnormal cervical cells before they turn into cancer, at a tenth of the usual cost.

A Paris private equity firm whose life sciences team, through its BioDiscovery funds, invests in European and US drug and medtech companies. Its life sciences portfolio includes the cancer T-cell therapy company T-Knife.

AOA Dx is developing a blood test to detect ovarian cancer early, based on fat-sugar molecules called glycolipids that tumours shed.

Aqemia combines physics-based calculations with generative artificial intelligence to invent new drug molecules, working both on its own projects and with large drug companies such as Sanofi.

Swiss linker-technology company (AraLinQ) acquired by Taiho for up to $1.14B; first clinical ADC ARC-02 (CD79b) dosed in June 2026.

Arcellx developed anito-cel, a CAR T-cell therapy for multiple myeloma that reprogrammes a patient's own immune cells to attack a marker called BCMA. Gilead bought the company in 2026 for about $7.8 billion ahead of a possible US approval.

A Chicago venture firm that starts and funds science-heavy biotech companies. Several of its companies work on cancer drugs, cancer cell therapies and cancer diagnostics.

Ariceum Therapeutics is a Berlin company developing a treatment that carries the alpha-emitting isotope actinium-225 to small cell lung cancer and Merkel cell skin cancer. Its first human trial began in late 2025.

Arpeggio Bio uses AI on large RNA-sequencing datasets to find drugs against transcription factors, the hard-to-hit proteins that switch cancer genes on, with a first programme in immunotherapy-resistant melanoma.

Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer.

ARTBIO makes cancer treatments that deliver short-range alpha radiation from lead-212 directly to tumour cells, starting with prostate cancer. Its first medicine is in early human trials, currently paused by the company while it reviews data.

Asher Bio engineers immune-stimulating molecules that switch on only one type of immune cell, such as killer T cells, so the drug is more potent against tumours and causes fewer side effects.

Ataraxis AI analyses digitised breast tumour slides with artificial intelligence to estimate how likely a cancer is to return and whether chemotherapy is likely to help, returning results in a day without using up tissue.